by TractManager | Jul 30, 2020 | Emerging Technology Report
Dexamethasone is a glucocorticoid that is FDA-approved for numerous indications; it is under investigation for the treatment of COVID-19. Glucocorticoids are adrenocortical steroids that modify the body’s immune responses to diverse stimuli. Dexamethasone is...
by TractManager | Jul 29, 2020 | Health Technology Assessment
Focus of the Report: This report evaluates the efficacy and safety of the gene replacement therapy onasemnogene abeparvovec-xioi (Zolgensma or AVXS-101) for treatment of patients with spinal muscular atrophy (SMA) type 1.Technology Description: Onasemnogene...
by TractManager | Jul 23, 2020 | Health Technology Assessment
Focus of the Report: This report compares the effectiveness and safety of skin substitutes (cellular and acellular) as an addition to standard wound care (SWC) with SWC alone and compared with the adjunct use of alternative skin substitute products to treat chronic or...
by TractManager | Jul 22, 2020 | Emerging Technology Report
Ayvakit (avapritinib) is an oral potent and selective inhibitor of activated KIT and PDGFRA mutant kinases, particularly activation loop mutations and highly resistant PDGFRA D842V mutation. It is indicated for the treatment of adults with unresectable or metastatic...
by TractManager | Jul 6, 2020 | Emerging Technology Report
Fenfluramine is a selective serotonin reuptake inhibitor (SSRI) indicated for the treatment of seizures associated with Dravet syndrome in patients aged 2 years and older. If you have a Hayes login, click here to view the full report on the Knowledge...
Recent Comments